A PILOT STUDY OF THERAPY WITH PIOGLITAZONE PRIOR TO HCV TREATMENT IN HIV-1 AN

HIV-1 AN 患者在 HCV 治疗前使用吡格列酮治疗的试点研究

• 批准号: 8166569
• 负责人: RICHARD K. STERLING
• 金额: $ 0.29万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8166569
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; HIV; HIV-1; Hepatitis C; Hepatitis C virus; Institutes; Institution; Insulin Resistance; Pilot Projects; Pioglitazone; Research; Research Personnel; Resources; Retreatment; Ribavirin; Source; United States National Institutes of Health; arm; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5239 is a single-arm, 2-step pilot study in which prior nonresponders to peginterferon (PEG-IFN) and ribavirin (RBV) therapy, with documented insulin resistance, are treated with pioglitazone prior to instituting hepatitis C retreatment. Subjects will receive 24 to 28 weeks of pioglitazone followed by continued pioglitazone therapy with PEG-IFN/RBV for up to an additional 48 weeks. Subjects will be evaluated 24 weeks after completion of hepatitis C virus (HCV) and HIV treatment to assess for sustained virologic response (SVR).

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 A5239 是一项单组、分两步的试点研究，其中对先前对聚乙二醇干扰素 (PEG-IFN) 和利巴韦林 (RBV) 治疗无反应且记录有胰岛素抵抗的患者在开始丙型肝炎再治疗之前先用吡格列酮治疗。受试者将接受 24 至 28 周的吡格列酮治疗，然后继续使用 PEG-IFN/RBV 进行最多 48 周的吡格列酮治疗。受试者将在丙型肝炎病毒 (HCV) 和 HIV 治疗完成后 24 周接受评估，以评估持续病毒学应答 (SVR)。